FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns
Executive Summary
The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger
You may also be interested in...
Octapharma Expects To Have Octagam Back On the Market By Year's End
The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.
Octapharma Expects To Have Octagam Back On the Market By Year's End
The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.
Talecris Tries Merger Route Again; Plans Combination With Spain's Grifols
Deal would increase Talecris' plasma-collection capabilities while providing an exit to VC backer Cerberus.